FDA ONP Leadership On Switches Could Benefit Chronic Therapies
This article was originally published in The Tan Sheet
The recent elevation of FDA's OTC drug division to office status sets the stage for the unit to take a more prominent role in evaluating Rx-to-OTC switches for chronic conditions
You may also be interested in...
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning